MitoCareX Bio
Novel Therapies for Hard-to-treat Resistant Cancers
StartupMitoCareX Bio is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2022. Novel Therapies for Hard-to-treat Resistant Cancers. MitoCareX Bio was founded by Alon Silberman. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
Product stage: R&D.
- StageAcquired
- ProductR&D
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last RoundUndisclosed
Alon SilbermanFounder & CSO
2 articles covered by sources including www.nasdaq.com,
www.globenewswire.com.
What does MitoCareX Bio do?
MitoCareX Bio is a drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family). To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with their proteins of interest, it uses its advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. The selected hit candidates are then progressed along the pre-clinical path.
Who founded MitoCareX Bio?
MitoCareX Bio was founded in 2022 by Alon Silberman (Founder & CSO).
What sector is MitoCareX Bio in?
MitoCareX Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is MitoCareX Bio located?
MitoCareX Bio is based in Tel Aviv-Yafo, Israel, Center District.